Relypsa Obtains $70,000,000 Series B Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=85cd9eb8-1139-4df2-9957-272cdbefa9d8&Preview=1 - Date
9/13/2010 - Company Name
Relypsa - Mailing Address
5301 Patrick Henry Drive Santa Clara, CA 95054 - Company Description
Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in renal and cardiovascular disease. The company’s most advanced therapeutic programs include a novel potassium binder for treatment of hyperkalemia, known as ILY-105, as well as a novel sodium binder, ILY102, for the potential treatment of congestive heart failure. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform. - Website
http://www.relypsa.com - Transaction Type
Venture Equity - Transaction Amount
$70,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds from the financing will support the advancement of Relypsa’s lead compound, RLY5016, through pivotal clinical studies. - M&A Terms
- Venture Investor
New Leaf Venture Partners - Venture Investor
5AM Ventures - Venture Investor
OrbiMed - Venture Investor
Delphi Ventures
